We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+25.66%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.77B
AUM Growth
+$373M
Cap. Flow
-$163M
Cap. Flow %
-2.41%
Top 10 Hldgs %
45.13%
Holding
79
New
15
Increased
25
Reduced
7
Closed
10

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$108M
2
IMTX icon
Immatics
IMTX
+$99.3M
3
MRUS
Merus
MRUS
+$70.4M
4
DYN icon
Dyne Therapeutics
DYN
+$69.9M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$63.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$398M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$314M
3
CLDX icon
Celldex Therapeutics
CLDX
+$137M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$98.5M
5
VCEL icon
Vericel Corp
VCEL
+$70.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRML
51
DELISTED
Tourmaline Bio
TRML
$17M 0.25%
741,656
+342,806
+86% +$12.1M
ROIV icon
52
Roivant Sciences
ROIV
$26.2B
$15.3M 0.23%
1,454,273
– –
VRDN icon
53
Viridian Therapeutics
VRDN
$2.67B
$10.6M 0.16%
605,816
– –
ACET icon
54
Adicet Bio
ACET
$74.7M
$9.72M 0.14%
258,414
– –
RGNX icon
55
Regenxbio
RGNX
$708M
$7.37M 0.11%
+350,000
New +$6.23M
SLRN
56
DELISTED
ACELYRIN
SLRN
$6.6M 0.1%
978,310
– –
EXAS
57
DELISTED
Exact Sciences
EXAS
$6.56M 0.1%
+95,000
New +$6.01M
ALUR
58
DELISTED
Allurion Technologies
ALUR
$6.05M 0.09%
138,308
– –
IMUX icon
59
Immunic
IMUX
$195M
$6.03M 0.09%
456,772
+23,246
+5% +$302K
MIST icon
60
Milestone Pharmaceuticals
MIST
$152M
$5.83M 0.09%
3,256,102
– –
GKOS icon
61
Glaukos
GKOS
$10.6B
$5.54M 0.08%
+58,791
New +$5.25M
SGMT icon
62
Sagimet Biosciences
SGMT
$559M
$5.42M 0.08%
+999,147
New +$7.18M
LRMR icon
63
Larimar Therapeutics
LRMR
$432M
$4.93M 0.07%
+650,000
New +$5.06M
SABS icon
64
SAB Biotherapeutics
SABS
$355M
$4.17M 0.06%
917,827
-1
-0% -$6
XGN icon
65
Exagen
XGN
$166M
$2.39M 0.04%
1,504,602
– –
XAIR icon
66
Beyond Air
XAIR
$3.86M
$2.1M 0.03%
+3,012
New +$2.07M
CUTR
67
DELISTED
Cutera, Inc.
CUTR
$1.96M 0.03%
1,331,776
-485,809
-27% -$1.26M
ARYD
68
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.44M 0.02%
127,970
– –
RCKTW icon
69
Rocket Pharmaceuticals Warrant
RCKTW
$288K
$105K ﹤0.01%
350,000
– –
ALNY icon
70
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-1,640,559
Closed -$314M
APYX icon
71
Apyx Medical
APYX
$171M
– –
-1,025,963
Closed -$2.69M
CLDX icon
72
Celldex Therapeutics
CLDX
$3.28B
– –
-3,463,201
Closed -$137M
DHR icon
73
Danaher
DHR
$144B
– –
-118,584
Closed -$27.4M
GH icon
74
Guardant Health
GH
$22.6B
– –
-492,977
Closed -$13.3M
SGHT icon
75
Sight Sciences
SGHT
$412M
– –
-164,806
Closed -$850K
1 2
3
4

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return

RTW Investments's Q1 2024 Portfolio in Review

As of Q1 2024, RTW Investments held 79 positions worth $6.77B, up 5.8% from $6.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RTW Investments's Q1 2024 filing shows 15 new, 25 increased, 7 reduced and 10 closed positions. Its largest new stake was Stryker: 321,000 shares worth $115M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $398M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q1 2024 buy was Stryker: 321,000 shares worth $115M.
  • RTW Investments added most to Immatics in Q1 2024, an estimated $99.3M increase.
  • RTW Investments's biggest Q1 2024 reduction was Madrigal Pharmaceuticals, cutting an estimated $98.5M.
  • RTW Investments fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $398M.
  • RTW Investments's ten largest holdings make up 45% of its $6.77B portfolio in Q1 2024.
  • RTW Investments opened 15 new positions and closed 10 in Q1 2024.
  • RTW Investments's portfolio value rose 5.8% quarter-over-quarter to $6.77B.

Based on RTW Investments's 13F filing for Q1 2024, filed 15 May 2024.